KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$463.7 million.

  • Recursion Pharmaceuticals' Income towards Parent Company fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$463.7 million for FY2024, which was down 41.33% from -$328.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$84.6 million during FY2020, with a 5-year trough of -$463.7 million in FY2024.
  • Its 3-year average for Income towards Parent Company is -$343.7 million, with a median of -$328.1 million in 2023.
  • Data for Recursion Pharmaceuticals' Income towards Parent Company shows a maximum YoY tumbled of 120.39% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Income towards Parent Company stood at -$84.6 million in 2020, then crashed by 120.39% to -$186.5 million in 2021, then fell by 28.42% to -$239.5 million in 2022, then slumped by 36.99% to -$328.1 million in 2023, then crashed by 41.33% to -$463.7 million in 2024.